Fitness Champs Holdings Files 424B4 Prospectus for Its IPO
Fitness Champs Holdings (FCHL) filed its final 424B4 prospectus with the SEC on Nov. 20, 2026. Here is what the filing signals and what to check next.

Key takeaways
- Fitness Champs Holdings Ltd, which uses the ticker FCHL, filed a 424B4 final prospectus with the SEC on November 20, 2026.
- EDGAR lists the filing under accession number 0001493152-26-053458 and CIK 0002023796. The document is about 1 MB.
- A 424B4 is normally filed once an offering has been priced, so the filing points to an initial public offering at or near completion.
- The final terms, including price, share count and use of proceeds, are in the document itself. Readers should check those before drawing conclusions.
What was filed
Fitness Champs Holdings Ltd submitted its 424B4 on the afternoon of Friday, November 20, 2026, according to the SEC’s EDGAR system. The filing was picked up by EDGAR’s feed of final IPO prospectuses and by a full-text search for the phrase “initial public offering” across the past seven days. That match indicates the document describes the company’s first sale of shares to the public.
The EDGAR record shows the issuer’s ticker as FCHL. Other details of the offering are contained in the prospectus body. This article does not restate figures that have not been verified against it.
What the 424B4 prospectus tells investors
Form 424B4 is the prospectus that issuers file under Rule 424(b)(4) after pricing. It supersedes the preliminary prospectus that circulated during marketing. For anyone reviewing IPO pricing, it is the authoritative record of the deal’s final terms.
Several sections deserve a close read:
| Section | Why it matters |
|---|---|
| Cover page and offering summary | Final price per share, number of shares offered and underwriting arrangements |
| Use of proceeds | Shows how much the company expects to raise and where the money will go |
| Dilution | Shows the gap between the offering price and the net tangible book value per share |
| Capitalization | Shows the share count and balance sheet after the deal |
| Risk factors | Company-specific and market risks, updated from the preliminary document |
Comparing the final document with the earlier preliminary prospectus is the standard way to see whether the range moved, the share count changed or the terms were revised during the marketing period.
Who is affected
The most immediate audience is the investors allocated shares in the offering and the existing holders whose stakes are diluted by new issuance. Analysts and market participants who track recent listings will also be watching the first trading sessions. The first-day performance of a newly priced IPO often draws attention, but it says little about the company’s longer-term fundamentals.
A related filing in the same search
The same EDGAR search for final IPO prospectuses also returned a 424B4 filed on November 19, 2026 under the name Anthropic, PBC, listed with the ticker ANT and CIK 0002130357. It is a separate issuer and a separate transaction, and its terms are not covered here. Its appearance shows that final prospectuses are being filed back to back this week.
What to watch next
- Trading debut: whether and when FCHL begins trading, and how the shares perform relative to the offering price.
- The full terms: the offering price, total proceeds and the underwriters’ role, as set out in the prospectus.
- Post-listing obligations: the company will need to meet public-company reporting requirements, including periodic filings with the SEC.
In general commentary provided to Floto Review, Andy Altahawi, undefined of Adamson Brothers Corp., which sponsors this publication, said: “The registration statement is only the start. Issuers that plan for quarterly reporting, internal controls and Regulation FD from the first draft of the S-1 or F-1 tend to have a much smoother first year as a public company.”
Floto Review will continue to review final prospectuses as they are filed. Nothing in this article is investment advice.
Prepared with AI assistance from public sources and reviewed under our editorial policy. Not investment advice.
